John T Poirier

researcher

John T Poirier is …
instance of (P31):
humanQ5

External links are
P496ORCID iD0000-0001-9795-5644

P735given nameJohnQ4925477
JohnQ4925477
P106occupationresearcherQ1650915
P21sex or gendermaleQ6581097

Reverse relations

author (P50)
Q92290257A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals
Q92111772Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
Q40145604Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.
Q92596446Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Q37042256CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Q47576454CRISPR Libraries and Screening.
Q40336402Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.
Q91838895Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
Q53316010Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.
Q42740602Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy.
Q36042596DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
Q36036608Design, execution, and analysis of pooled in vitro CRISPR/Cas9 screens
Q97686528Emergence of a High-Plasticity Cell State during Lung Cancer Evolution
Q97535525Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer
Q35238397Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer
Q49832498Fc-mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.
Q99552320Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors
Q100535021Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks
Q112702380Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts
Q90659981HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Q53400102Histone Code Aberrancies in Small Cell Lung Cancer.
Q91839128Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
Q41992348Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
Q96431247Lineage reversion drives WNT independence in intestinal cancer
Q92377180MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer
Q43627373MYC, MAX, and small cell lung cancer.
Q92709040Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Q90680882NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Q89527853New Approaches to SCLC Therapy: From the Laboratory to the Clinic
Q39934413Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Q40208474Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer
Q60907546ONECUT2 is a driver of neuroendocrine prostate cancer
Q37339265P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.
Q40640808PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Q64229921Peptide-based PET quantifies target engagement of PD-L1 therapeutics
Q35224606Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group
Q92720881Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts
Q57181405ProteomeGenerator: A framework for comprehensive proteomics based on de novo transcriptome assembly and high-accuracy peptide mass spectral matching
Q36128151Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis
Q35170413RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Q41848124RET mutations in neuroendocrine tumors: including small-cell lung cancer
Q35878431Rapamycin rescues ABT-737 efficacy in small cell lung cancer
Q89637977Regenerative lineages and immune-mediated pruning in lung cancer metastasis
Q112708650Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer
Q37463325Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.
Q35662216Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy
Q52813956Small-cell lung cancer in 2016: Shining light on novel targets and therapies.
Q100535047TMEM41B is a pan-flavivirus host factor
Q57462253Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
Q48251246Target engagement imaging of PARP inhibitors in small-cell lung cancer.
Q38791259Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts.
Q63866205Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
Q112350511ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer
Q38769421Unravelling the biology of SCLC: implications for therapy
Q39776608Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer.
Q90414077Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development
Q91388498Virus-Receptor Interactions: Structural Insights For Oncolytic Virus Development

Search more.